NR4A1 and neoplasm: Since the tumor was hormone receptor positive and HER‐2 negative, she was offered, as adjuvant‐like treatment, a combination of CDK4/6 inhibitor with endocrine therapy, tolerating the treatment well and being disease‐free in her last follow‐up.12